Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140

Journal of Virology

Volumn 75, Issue 2, 2001, Pages 645-653

  Earl, P L ^a   Sugiura, W ^a   Montefiori, D C ^a   Broder, C C ^a   Lee, S A ^a   Wild, C ^a   Lifson, J ^a   Moss, B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RABBIT; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CROSS REACTIONS; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MACACA MULATTA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RABBITS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS REPLICATION;

EID: 0035168058     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.2.645-653.2001     Document Type: Article

References (79)

1. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
2. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells
3. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
4. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
5. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
6. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network
7. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
8. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
9. + T-cell lines vs. primary macrophages
10. Antigenic implications of HIV-1 Env quaternary structure
11. An adenovirus simian immunodeficiency virus Env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
12. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
13. A vaccine for HIV type 1: The antibody perspective
14. The antibody response in HIV-1 infection
15. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts
16. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
17. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
18. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
19. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
20. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
21. A dualtropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
22. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein
23. Native oligomeric forms of human immunodeficiency virus type 1 envelope glycoprotein elicit a diverse array of monoclonal antibody reactivities
24. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
25. Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV
26. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
27. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
28. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus
29. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus
30. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
31. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines
32. Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile
33. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
34. Immunity to retroviral infection the Friend virus model
35. Toward an understanding of the correlates of protective immunity to HIV infection
36. HIV vaccines - Where are we going?
37. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
38. Progress in the development of an HIV-1 vaccine
39. Utility of SHIV for testing HIV-1 vaccine candidates in macaques
40. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
41. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
42. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
43. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development
44. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation
45. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
46. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120
47. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immuno-deficiency virus type 1
48. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
49. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
50. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
51. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
52. Cross-neutralization activity against divergent human immunodeficiency virus type 1 isolates induced by the pg41 sequence ELDKWAS
53. In vitro antigen challenge of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 envelope
54. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
55. Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development
56. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection
57. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1
58. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers
59. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques
60. Antibody epitopes sensitive to the state of human immunodeficiency virus type 1 gp41 oligomerization map to a putative alpha-helical region
61. A simple method of estimating fifty percent endpoints
62. A role for carbohydrates in immune evasion in AIDS
63. The humoral response to oligomeric human immunodeficiency virus type 1 envelope protein
64. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
65. DNA vaccines for immunodeficiency viruses
66. The role of cellular immunity in protection against HIV infection
67. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
68. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
69. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
70. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
71. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
72. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates
73. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120
74. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
75. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines
76. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160
77. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen
78. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein
79. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins